Placeholder canvas

Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Apr 12, 2021 | Deal of the Month, Partnership Deals

March 2021 Top Biopharma Deal Upfront
Debiopharm development and commercialization deal with Merck KGaA for Xevinapant

Highlighted Deal Financial Comps

Date Announced:

Mar. 1, 2021

Total Deal Value:


Upfront Cash:

$227M (EUR 188M)

Upfront Equity:


Option Payments:


Total Milestones:

$856M (EUR 710M), reg. & sales



Cost & Profit Split:


Deal Synopsis

The Asset:

Phase III Xevinapant (Debio 1143) oral Inhibitor of Apoptosis Proteins (IAP) antagonist for the treatment of advanced squamous cell carcinoma of the head and neck.

Deal Structure:

Development and Commercial License

Partnership Features:

Shared costs for Phase III

Deal Details:

  • Debiopharm granted Merck exclusive, worldwide rights to develop and commercialize Xevinapant for the treatment of advanced squamous cell carcinoma of the head and neck.
  • Both companies will co-fund the ongoing Phase III registrational TrilynX study.
  • Debiopharm will receive EUR 188M ($227M) up front and is eligible to receive up to EUR 710M ($856M) in regulatory and commercial milestones, plus royalties.

Last Month:

Congrats to Debiopharm and Merck KGaA for landing the DealForma March 2021 Top Biopharma Deal of the Month. The Deal of the Month for February 2021 was the Vir – GSK expansion in to influenza. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.


Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Biopharma Venture Investment Through Q3 2023

Biopharma Venture Investment Through Q3 2023

Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...

Biopharma M&A Through Q3 2023

Biopharma M&A Through Q3 2023

This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...

Biopharma R&D Partnerships – Q3 2023 Review

Biopharma R&D Partnerships – Q3 2023 Review

Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...